Chadi convenes yet another expert roundtable to discuss CLL with a few returning guests as well as a physician-patient: Liz Brem, MD, assistant clinical professor of hematology, UC Irvine, Alan Skarbnik, MD, director of the lymphoma and CLL program, Novant Health (Charlotte, NC), and Brian Koffman, MDCM, FCFP, DABFM, MS Ed, executive vice president and chief medical officer, CLL Society. The group begins by stating that patients have little-to-no participation in treatment guidelines for CLL, positing whether treatment is necessary for early-stage disease at all, debating what testing procedures should be done after diagnosis, and concluding with what place MRD has in the treatment paradigm. Dr. Koffman shares his personal story of waiting as long as possible to begin his unconventional treatment course (including first remission allogeneic transplant) and the group discusses whether the limited evidence base for this course matters or not. Dissecting the intricacies of treating CLL, especially from the patient perspective, is no easy task and these experts do a very thorough job of detailing the discussion points that matter most.